KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).

Authors: Ken Kato, Toshihiko Doi, Antoine Adenis, Manish A. Shah, Peter C. Enzinger, Lin Shen, Tatiane Cristine Ishida, Leah Suttner, Kanu Sharan, Pooja Bhagia, Jong-Mu Sun

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4209

Source: Full article

---

Abstract

TPS4209